Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 292 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Extensive Stage Lung Cancer Clear all
Terminated Phase 2 Interventional Results available

Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC)

NCT02934503
View directory record Official record
Conditions
Small Cell Lung Cancer (SCLC)
Interventions
Pembrolizumab, Cisplatin, Carboplatin, Etoposide, Radiation therapy
Biological · Drug · Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
19 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 15, 2021 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Phase 2 Interventional Results available

AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer

NCT00528645
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Cancer, Lung Metastases, Malignant Pleural Effusion, Recurrent Small Cell Lung Cancer
Interventions
saracatinib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Jul 22, 2026, 10:45 AM EDT
Active, not recruiting Phase 2 Interventional Results available

MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer

NCT06227546
View directory record Official record
Conditions
Extensive-stage Small-cell Lung Cancer
Interventions
MGC018
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Phase 2 Interventional

Gleevec Maintenance Therapy After Induction Irinotecan and Cisplatin in Patients With C-Kit Positive Extensive SCLC

NCT00156286
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Gleevec
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 15, 2010 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy With or Without Filgrastim in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer

NCT00028925
View directory record Official record
Conditions
Lung Cancer
Interventions
filgrastim, carboplatin, topotecan hydrochloride, WBRT
Biological · Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
23
States / cities
Scottsdale, Arizona • Washington D.C., District of Columbia • Jacksonville, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced Jul 22, 2026, 10:45 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer

NCT02748889
View directory record Official record
Conditions
Small Cell Lung Cancer ( SCLC )
Interventions
Carboplatin, Etoposide, MPDL3280A
Drug · Biological
Lead sponsor
Giuseppe Giaccone
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 1, 2018 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Phase 1 Interventional

Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer

NCT00036790
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Colorectal Cancer, Head and Neck Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic/Myeloproliferative Diseases, Prostate Cancer, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
doxorubicin hydrochloride, motexafin gadolinium
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Jul 22, 2026, 10:45 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Carboplatin and Etoposide in Combination With Vorinostat for Patients With Extensive Stage Small Cell Lung Cancer

NCT00702962
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Vorinostat, Carboplatin, Etoposide
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 21, 2018 · Synced Jul 22, 2026, 10:45 AM EDT
Recruiting Phase 2 Interventional

Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer

NCT07057791
View directory record Official record
Conditions
Extensive Stage Lung Small Cell Cancer
Interventions
Ivonescimab 10 mg/kg, Ivonescimab 20 mg/kg
Drug
Lead sponsor
PrECOG, LLC.
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
11
States / cities
Miami, Florida • Baltimore, Maryland • Morristown, New Jersey + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Phase 1 Interventional

Cisplatin, Etoposide and PI3K Inhibitor BKM120 in Treating Patients With Advanced Solid Tumors or Small Cell Lung Cancer

NCT02194049
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
BKM120, cisplatin, etoposide
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 8, 2018 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Phase 1 Interventional

A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer

NCT03898791
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
LY3295668 Erbumine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
16
States / cities
Fayetteville, Arkansas • Denver, Colorado • Tampa, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Phase 1 Interventional

Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the Pleura

NCT00019825
View directory record Official record
Conditions
Esophageal Cancer, Lung Cancer, Malignant Mesothelioma, Metastatic Cancer
Interventions
decitabine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Phase 3 Interventional

Topotecan in Treating Patients With Relapsed Small Cell Lung Cancer

NCT00003917
View directory record Official record
Conditions
Lung Cancer
Interventions
topotecan hydrochloride
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
53
States / cities
Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 48 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2014 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Phase 2 Interventional Results available

Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers

NCT01935336
View directory record Official record
Conditions
Adenocarcinoma of the Lung, Extensive Stage Small Cell Lung Cancer, Limited Stage Small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent Small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
Ponatinib
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced Jul 22, 2026, 10:45 AM EDT
Withdrawn Phase 2 Interventional

Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial

NCT05161533
View directory record Official record
Conditions
Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Carboplatin, Cisplatin, Durvalumab, Etoposide, Hypofractionated Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration
Drug · Biological · Radiation + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Phase 3 Interventional

Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer

NCT00006349
View directory record Official record
Conditions
Cognitive/Functional Effects, Delirium, Depression, Lung Cancer, Radiation Toxicity
Interventions
vitamin E, donepezil hydrochloride, placebo
Dietary Supplement · Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
15
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Jul 22, 2026, 10:45 AM EDT
Withdrawn Phase 2 Interventional

INNO-206 in Patients With Small Cell Lung Cancer (SCLC)

NCT00472771
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
INNO-206
Drug
Lead sponsor
CytRx
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
7
States / cities
Chicago, Illinois • Billings, Montana • Albany, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2012 · Synced Jul 22, 2026, 10:45 AM EDT
Terminated Phase 1 Interventional

Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED)

NCT03116971
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
M3814, Cisplatin, Etoposide
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
16
States / cities
Mesa, Arizona • Santa Rosa, California • Whittier, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2020 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Phase 3 Interventional

Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults

NCT00043927
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
topotecan/cisplatin, etoposide/cisplatin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
760 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
66
States / cities
Hoover, Alabama • Chula Vista, California • Fountain Valley, California + 57 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2013 · Synced Jul 22, 2026, 10:45 AM EDT
Active, not recruiting Phase 2 Interventional

Ipilimumab and Nivolumab in Recurrent Extensive Stage Small Cell Lung Cancer After Receiving Platinum-based Chemotherapy

NCT03670056
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Combination immunotherapy with Ipilimumab and Nivolumab
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 19, 2025 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Phase 1 Interventional

Thalidomide and Docetaxel in Treating Patients With Advanced Cancer

NCT00049296
View directory record Official record
Conditions
Cancer
Interventions
docetaxel, thalidomide
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 10, 2010 · Synced Jul 22, 2026, 10:45 AM EDT
Active, not recruiting Phase 2 Interventional

Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

NCT05280470
View directory record Official record
Conditions
Extensive-stage Small-cell Lung Cancer
Interventions
Ifinatamab Deruxtecan (I-DXd)
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
16
States / cities
Springdale, Arkansas • Jacksonville, Florida • Tampa, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Jul 22, 2026, 10:45 AM EDT
Recruiting Phase 2 Interventional

Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

NCT07339059
View directory record Official record
Conditions
Small Cell Lung Cancer ( SCLC ), Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Interventions
Sacituzumab govitecan, Atezolizumab, Durvalumab
Drug
Lead sponsor
Bindu R Potugari
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Jul 22, 2026, 10:45 AM EDT
Not listed Phase 3 Interventional

Study of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer (The MATISSE Study)

NCT01555710
View directory record Official record
Conditions
Extensive-Stage Small Cell Lung Cancer
Interventions
Carboplatin, Palifosfamide-tris, Etoposide
Drug
Lead sponsor
Alaunos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
548 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
40
States / cities
Birmingham, Alabama • Los Angeles, California • Santa Rosa, California + 36 more
Source: ClinicalTrials.gov public record
Updated May 20, 2013 · Synced Jul 22, 2026, 10:45 AM EDT